+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bradykinin Receptor Antagonists Market - Global Forecast 2026-2032- Product Image
Bradykinin Receptor Antagonists Market - Global Forecast 2026-2032- Product Image
New

Bradykinin Receptor Antagonists Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 188 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6085096
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The bradykinin receptor antagonists market is undergoing significant evolution, propelled by scientific advances, regulatory changes, and growing clinical demand across inflammatory and vascular-mediated diseases. This report provides senior decision-makers with an incisive analysis of current trends, commercial challenges, and actionable opportunities shaping the future of this therapeutic class.

Market Snapshot: Growth Trajectory and Outlook

The Bradykinin Receptor Antagonists Market grew from USD 205.17 million in 2025 to USD 230.99 million in 2026. It is expected to continue growing at a CAGR of 14.37%, reaching USD 525.45 million by 2032. This accelerated expansion is driven by a robust pipeline, increasing adoption in chronic and acute indications, and the diversification of delivery modalities.

Scope & Segmentation

  • Modality Types: Biologics, including monoclonal antibodies and peptide therapeutics; small molecules, featuring synthetically optimized oral agents.
  • Indication Focus: Chronic cough (covering idiopathic and refractory types), hereditary angioedema (both acute attacks and prophylaxis), and diabetic nephropathy, among others.
  • Administration Routes: Oral (capsule, tablet), inhalation, parenteral (intravenous, subcutaneous), and topical formats.
  • Distribution Channels: Hospital pharmacy (inpatient, outpatient), online pharmacy (direct-to-patient, pharmacy pickup), and retail pharmacy (chain, independent outlets).
  • End-User Segments: Ambulatory care (clinics, diagnostic centers), home care (home nursing, self-administration), and hospital settings (private, public institutions).
  • Geographic Coverage: Americas, Europe Middle East & Africa, and Asia-Pacific, each with distinct regulatory, payer, and manufacturing factors.
  • Technologies Addressed: Advances in protein engineering, peptide stabilization, medicinal chemistry, digital health for adherence and remote monitoring, and biologic manufacturing optimization.

Key Takeaways

  • Bradykinin receptor antagonists are now a differentiated mechanism-of-action within inflammatory and vascular disorders, benefiting from enhanced selectivity and expanding clinical targets.
  • The pipeline is diversifying via biologics, peptides, and small molecules, using biomarker-driven endpoints to demonstrate real-world improvements and support reimbursement discussions.
  • Technological innovation has yielded more stable biologics and higher oral bioavailability, addressing both patient preferences and administration constraints.
  • Strategic collaborations with contract manufacturers and digital health firms are accelerating product launch and improving patient monitoring and support models.
  • Regional commercialization requires tailored evidence packages and an understanding of varying health technology assessments and payer expectations to optimize access.
  • Integrated evidence generation—including pragmatic clinical design, segmentation strategies, and health economic modeling—is central to substantiating value in payer negotiations.

Tariff Impact on Supply Chain and Commercialization

The 2025 tariffs and evolving trade policies have introduced new complexities in sourcing, logistics, and contracting. Tariff adjustments impact costs for active pharmaceutical ingredients, specialty reagents, and biologics, prompting developers to diversify suppliers, enhance inventory planning, and consider reshoring where feasible. Proactive risk management is vital, as tariff-related costs are pushing payers to scrutinize value and contract structures more closely.

Methodology & Data Sources

The research applies a rigorous mixed-methods approach, drawing on expert interviews with clinical, regulatory, payer, and supply chain leaders, complemented by secondary synthesis of peer-reviewed studies, guidance documents, and clinical trial data. Thematic conclusions have been vetted with key opinion leaders and cross-functional stakeholders to ensure practical, actionable insights.

Bradykinin Receptor Antagonists Market: Why This Report Matters

  • Offers a comprehensive, segmentation-driven outlook supporting investment, R&D, and commercialization strategy across global markets.
  • Equips leadership with insights into regulatory pathways, payer behaviors, and supply chain dynamics to mitigate emerging risks and accelerate time-to-market.

Conclusion

Bradykinin receptor antagonists are well-positioned to address complex clinical needs across multiple geographies, supported by scientific advances and pragmatic operational strategies. Sustained growth will depend on segment-focused innovation, robust supply chain planning, and tailored commercialization pathways.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Bradykinin Receptor Antagonists Market, by Type
8.1. Biologic
8.1.1. MAb
8.1.2. Peptide
8.2. Small Molecule
9. Bradykinin Receptor Antagonists Market, by Indication
9.1. Chronic Cough
9.1.1. Idiopathic Cough
9.1.2. Refractory Cough
9.2. Diabetic Nephropathy
9.3. Hereditary Angioedema
9.3.1. Acute Attack
9.3.2. Prophylaxis
10. Bradykinin Receptor Antagonists Market, by Route Of Administration
10.1. Inhalation
10.2. Oral
10.2.1. Capsule
10.2.2. Tablet
10.3. Parenteral
10.3.1. IV
10.3.2. SC
10.4. Topical
11. Bradykinin Receptor Antagonists Market, by End User
11.1. Ambulatory Care
11.1.1. Clinics
11.1.2. Diagnostic Centers
11.2. Home Care
11.2.1. Home Nursing
11.2.2. Self Administration
11.3. Hospital
11.3.1. Private Hospital
11.3.2. Public Hospital
12. Bradykinin Receptor Antagonists Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Bradykinin Receptor Antagonists Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Bradykinin Receptor Antagonists Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Bradykinin Receptor Antagonists Market
16. China Bradykinin Receptor Antagonists Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Abbott Laboratories
17.6. Bayer AG
17.7. BioCryst Pharmaceuticals, Inc.
17.8. Boehringer Ingelheim International GmbH
17.9. CSL Limited
17.10. Dyax Corp.
17.11. Elan Pharmaceuticals, Inc.
17.12. Ionis Pharmaceuticals, Inc.
17.13. Jerini AG
17.14. KalVista Pharmaceuticals, Inc.
17.15. Laboratoires Fournier S.A.
17.16. Merck & Co., Inc.
17.17. Novartis AG
17.18. Pfizer Inc.
17.19. Pharming Group N.V.
17.20. Pharvaris N.V.
17.21. Sanofi S.A.
17.22. SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.
17.23. Swedish Orphan Biovitrum AB
17.24. Takeda Pharmaceutical Company Limited
List of Figures
FIGURE 1. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY MAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY MAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY MAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY IDIOPATHIC COUGH, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY IDIOPATHIC COUGH, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY IDIOPATHIC COUGH, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY REFRACTORY COUGH, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY REFRACTORY COUGH, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY REFRACTORY COUGH, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY DIABETIC NEPHROPATHY, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY DIABETIC NEPHROPATHY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY DIABETIC NEPHROPATHY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ACUTE ATTACK, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ACUTE ATTACK, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ACUTE ATTACK, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY IV, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY IV, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY IV, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY SC, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY SC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY SC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME NURSING, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME NURSING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME NURSING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY SELF ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY SELF ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. AMERICAS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 100. AMERICAS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 101. AMERICAS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 102. AMERICAS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 103. AMERICAS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
TABLE 104. AMERICAS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
TABLE 105. AMERICAS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 107. AMERICAS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 108. AMERICAS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 109. AMERICAS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
TABLE 110. AMERICAS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
TABLE 111. AMERICAS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. NORTH AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 119. NORTH AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 120. NORTH AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 122. NORTH AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
TABLE 123. NORTH AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
TABLE 124. NORTH AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
TABLE 130. LATIN AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 132. LATIN AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 133. LATIN AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 134. LATIN AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 135. LATIN AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
TABLE 136. LATIN AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
TABLE 137. LATIN AMERICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 151. EUROPE BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 152. EUROPE BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 153. EUROPE BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 154. EUROPE BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 155. EUROPE BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
TABLE 156. EUROPE BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
TABLE 157. EUROPE BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 158. EUROPE BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 159. EUROPE BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 160. EUROPE BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 161. EUROPE BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
TABLE 162. EUROPE BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
TABLE 163. EUROPE BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 164. MIDDLE EAST BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 165. MIDDLE EAST BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 166. MIDDLE EAST BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 167. MIDDLE EAST BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 168. MIDDLE EAST BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
TABLE 169. MIDDLE EAST BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
TABLE 170. MIDDLE EAST BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 171. MIDDLE EAST BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 172. MIDDLE EAST BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 173. MIDDLE EAST BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 174. MIDDLE EAST BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
TABLE 175. MIDDLE EAST BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
TABLE 176. MIDDLE EAST BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 177. AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 178. AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 179. AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 180. AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 181. AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
TABLE 182. AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
TABLE 183. AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 184. AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 185. AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 186. AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 187. AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
TABLE 188. AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
TABLE 189. AFRICA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 190. ASIA-PACIFIC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 191. ASIA-PACIFIC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 192. ASIA-PACIFIC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 193. ASIA-PACIFIC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 194. ASIA-PACIFIC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
TABLE 195. ASIA-PACIFIC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
TABLE 196. ASIA-PACIFIC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 197. ASIA-PACIFIC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 198. ASIA-PACIFIC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 199. ASIA-PACIFIC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 200. ASIA-PACIFIC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
TABLE 201. ASIA-PACIFIC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
TABLE 202. ASIA-PACIFIC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 203. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 204. ASEAN BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 205. ASEAN BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 206. ASEAN BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 207. ASEAN BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 208. ASEAN BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
TABLE 209. ASEAN BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
TABLE 210. ASEAN BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 211. ASEAN BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 212. ASEAN BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 213. ASEAN BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 214. ASEAN BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
TABLE 215. ASEAN BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
TABLE 216. ASEAN BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 217. GCC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 218. GCC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 219. GCC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 220. GCC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 221. GCC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
TABLE 222. GCC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
TABLE 223. GCC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 224. GCC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 225. GCC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 226. GCC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 227. GCC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
TABLE 228. GCC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
TABLE 229. GCC BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 230. EUROPEAN UNION BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 231. EUROPEAN UNION BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 232. EUROPEAN UNION BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 233. EUROPEAN UNION BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 234. EUROPEAN UNION BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
TABLE 235. EUROPEAN UNION BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
TABLE 236. EUROPEAN UNION BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 240. EUROPEAN UNION BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
TABLE 241. EUROPEAN UNION BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
TABLE 242. EUROPEAN UNION BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 243. BRICS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 244. BRICS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 245. BRICS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 246. BRICS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 247. BRICS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
TABLE 248. BRICS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
TABLE 249. BRICS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 250. BRICS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 251. BRICS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 252. BRICS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 253. BRICS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
TABLE 254. BRICS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
TABLE 255. BRICS BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 256. G7 BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 257. G7 BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 258. G7 BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 259. G7 BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 260. G7 BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
TABLE 261. G7 BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
TABLE 262. G7 BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 263. G7 BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 264. G7 BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 265. G7 BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 266. G7 BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
TABLE 267. G7 BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
TABLE 268. G7 BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 269. NATO BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 270. NATO BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 271. NATO BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 272. NATO BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 273. NATO BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
TABLE 274. NATO BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
TABLE 275. NATO BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 276. NATO BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 277. NATO BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 278. NATO BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 279. NATO BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
TABLE 280. NATO BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
TABLE 281. NATO BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 282. GLOBAL BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 283. UNITED STATES BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 284. UNITED STATES BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 285. UNITED STATES BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 286. UNITED STATES BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 287. UNITED STATES BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
TABLE 288. UNITED STATES BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
TABLE 289. UNITED STATES BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 290. UNITED STATES BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 291. UNITED STATES BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 292. UNITED STATES BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 293. UNITED STATES BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY AMBULATORY CARE, 2018-2032 (USD MILLION)
TABLE 294. UNITED STATES BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
TABLE 295. UNITED STATES BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 296. CHINA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 297. CHINA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 298. CHINA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
TABLE 299. CHINA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 300. CHINA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY CHRONIC COUGH, 2018-2032 (USD MILLION)
TABLE 301. CHINA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
TABLE 302. CHINA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 303. CHINA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 304. CHINA BRADYKININ RECEPTOR ANTAGONISTS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 305. CHINA BRADYKININ RECEPTOR ANTAGONISTS MA

Companies Mentioned

  • Abbott Laboratories
  • Bayer AG
  • BioCryst Pharmaceuticals, Inc.
  • Boehringer Ingelheim International GmbH
  • CSL Limited
  • Dyax Corp.
  • Elan Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Jerini AG
  • KalVista Pharmaceuticals, Inc.
  • Laboratoires Fournier S.A.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Pharming Group N.V.
  • Pharvaris N.V.
  • Sanofi S.A.
  • SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages188
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 230.99 Million
Forecasted Market Value ( USD ) by 2032 $ 525.45 Million
Compound Annual Growth Rate14.3%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Drugs for Conn's Syndrome Market - Global Forecast 2026-2032 - Product Image

Drugs for Conn's Syndrome Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Medication for Dementia Symptoms Market - Global Forecast 2025-2030 - Product Image

Medication for Dementia Symptoms Market - Global Forecast 2025-2030

  • Report
  • 191 Pages
  • Global
From
Orexin Antagonist Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Orexin Antagonist Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Neuroregeneration Therapy Market - Global Strategic Business Report - Product Image

Neuroregeneration Therapy Market - Global Strategic Business Report

  • Report
  • 480 Pages
  • Global
From
Histatrol Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Histatrol Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.